EVD Drainage Data and Intracranial Pressure (ICP) Measurements - Trial NCT05546996
Access comprehensive clinical trial information for NCT05546996 through Pure Global AI's free database. This phase not specified trial is sponsored by Baylor College of Medicine and is currently Not yet recruiting. The study focuses on Hydrocephalus. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Baylor College of Medicine
Timeline & Enrollment
N/A
Jan 01, 2023
Dec 01, 2023
Primary Outcome
Exploratory outcome
Summary
Rhaeos, Inc. is initially targeting hydrocephalus, a life threatening condition caused by an
 abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard
 treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries.
 There is no technology available today that can easily assess CSF flow in shunts wirelessly,
 bedside, and without capital equipment until now.
 
 FlowSense, is a wireless, noninvasive thermal flow sensor that can be mounted on a patient's
 neck overlying the shunt to detect the presence and magnitude of CSF. Similar in size to a
 bandage, it is composed of soft, silicone with no hard edges. Data is wirelessly transmitted
 to a custom designed mobile app. With FlowSense, monitoring of shunt function can occur in
 clinics, in-patient settings, and emergency departments, thereby reducing unnecessary
 imaging, hospital length of stay, and readmission costs.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05546996
Device Trial